Antibacterial phage, phage peptides and methods of use thereof
The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.
1. A method of treating or reducing the incidence of a Staphylococcus aureus infection in a subject in need thereof, said method comprising administering to said subject an effective amount of a pharmaceutical composition, said pharmaceutical composition comprising:
a pharmaceutically acceptable carrier; and
a purified bacteriophage having a nucleic acid sequence of SEQ ID NO:560.
2. The method of claim 1 , wherein said pharmaceutical composition further comprises
(i) three additional purified phage selected from the group consisting of F391/08, F394/08, F488/08, F510/08, F387/08, F170/08, F168/08, F770/05, and F1245/05; or
(ii) three additional purified phage selected from the group consisting of F391/08, F387/08, F488/08, F510/08 and/or F770/05.
3. The method of claim 1 , wherein the infection is a nosocomial infection.
4. The method of claim 1 , wherein the pharmaceutical composition is administered topically.
5. The method of claim 1 , wherein the infection is an infection of the skin.
6. The method of claim 5 , wherein the infection is an infection associated with at least one condition selected from the group consisting of diabetic foot ulcer, scalded skin syndrome, pimples, and carbuncles.
7. The method of claim 6 , wherein the pharmaceutical composition is administered topically.
8. The method of claim 1 , wherein the infection is pneumonia or other infection of the respiratory tract.
9. The method of claim 8 , wherein the pharmaceutical composition is administered by inhalation.
10. The method of claim 9 , wherein administration by inhalation uses a pump, a spray, or a nebulizer; or wherein the pharmaceutical composition for administration by inhalation comprises a dry powder inhaler or an aerosol spray.
11. The method of claim 1 , wherein the infection is an infection associated with at least one condition selected from the group consisting of gastroenteritis, osteomyelitis, endocarditis, and peritonitis.
12. The method of claim 11 , wherein the pharmaceutical composition is administered orally or parenterally.
13. The method of claim 1 , wherein the infection is an infection associated with at least one condition selected from the group consisting of meningitis or other infection of the cerebrospinal fluid, toxic shock syndrome, bacteremia, and sepsis.
14. The method of claim 13 , wherein the pharmaceutical composition is administered intravenously.
15. The method of claim 1 , wherein the infection is an infection of the urinary tract.
16. The method of claim 15 , wherein the pharmaceutical composition is administered by a catheter.
17. The method of claim 1 , wherein the subject is a human.
18. The method of claim 1 , further comprising administering to said subject an antibiotic for treating said bacterial infection.
19. The method of claim 1 , wherein said pharmaceutical composition further comprises one of more additional bacteriophage known to have antibacterial or antimicrobial activity against Staphylococcus aureus.
20. The method of claim 1 , wherein said pharmaceutical composition further comprises one of more additional bacteriophage known to have antibacterial or antimicrobial activity against a bacterium other than Staphylococcus aureus.
21. The method of claim 1 , wherein said Staphylococcus aureus infection is an infection by a methicillin-resistant strain of Staphylococcus aureus (MRSA).
22. The method of claim 21 , further comprising administering to said subject at least one antibiotic known to have antibacterial or antimicrobial activity against MRSA.
23. The method of claim 22 , wherein said antibiotic is selected from the group consisting of vancomycin, teicoplanin, clindamycin, and trimethoprim-sulfamethoxazole.